Axsome Therapeutics, Inc. $AXSM Stock Sold by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 58.2% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 5,888 shares of the company’s stock after selling 8,183 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Axsome Therapeutics were worth $1,086,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in Axsome Therapeutics in the second quarter valued at $759,695,000. OneDigital Investment Advisors LLC purchased a new stake in shares of Axsome Therapeutics during the 2nd quarter worth about $1,906,000. Baird Financial Group Inc. purchased a new stake in shares of Axsome Therapeutics during the 2nd quarter worth about $2,497,000. Lisanti Capital Growth LLC acquired a new stake in shares of Axsome Therapeutics during the 2nd quarter valued at about $5,097,000. Finally, Legal & General Group Plc acquired a new stake in shares of Axsome Therapeutics during the 2nd quarter valued at about $8,095,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Trading Down 3.3%

Shares of NASDAQ AXSM opened at $144.37 on Friday. The company has a quick ratio of 1.34, a current ratio of 1.42 and a debt-to-equity ratio of 1.21. Axsome Therapeutics, Inc. has a 12-month low of $123.00 and a 12-month high of $260.19. The company has a 50-day moving average of $172.78 and a 200 day moving average of $196.98.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.38. The business had revenue of $259.69 million for the quarter, compared to analyst estimates of $249.19 million. Axsome Therapeutics had a negative net margin of 18.18% and a negative return on equity of 198.73%. The business’s revenue was up 51.9% on a year-over-year basis. During the same period last year, the company posted ($0.94) EPS. On average, sell-side analysts expect that Axsome Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on AXSM shares. Zacks Research upgraded Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. BMO Capital Markets started coverage on Axsome Therapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $310.00 price target on the stock. Morgan Stanley increased their price target on Axsome Therapeutics from $247.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 3rd. Mizuho reduced their target price on Axsome Therapeutics from $284.00 to $272.00 and set an “outperform” rating for the company in a research note on Wednesday, November 4th. Finally, Robert W. Baird reduced their target price on Axsome Therapeutics from $246.00 to $220.00 and set an “outperform” rating for the company in a research note on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $267.58.

Read Our Latest Analysis on Axsome Therapeutics

Insider Activity at Axsome Therapeutics

In related news, COO Mark Jacobson sold 10,000 shares of Axsome Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the transaction, the chief operating officer owned 10,000 shares in the company, valued at approximately $2,086,500. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 20.60% of the company’s stock.

Axsome Therapeutics Profile

(Free Report)

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

See Also

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.